Shein Shares Slide 9% in Hong Kong IPO Debut 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
OpenAI Rejects Apple Trade Secret Theft Claims 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
France Targets Shein, Temu With Fast-Fashion Fees 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Add as a preferred source on Google
Samsung Bioepis Co. Ltd.'s commercial partner Organon will supply its Hadlima autoimmune disease treatment to the United States after winning an order from the U.S. Department of Veterans Affairs. It was agreed that U.S.-based Organon would deliver the biosimilar Hadlima drugs for five years.
Organon will now deliver Hadlima biosimilar treatment to the Department of Veterans Affairs (V.A.). This well-known drug is mainly used for medicating rheumatoid arthritis, spondyloarthritis, and psoriasis. According to The Korea Economic Daily, AbbVie Inc., a pharmaceutical company headquartered in North Chicago, Illinois, developed the original drug.
Orders from the U.S.
The latest order was revealed by Organon, the partner company of Samsung Bioepis based in the U.S. On Wednesday, Feb. 21, the firm said that Organon won a bidding contract to supply Hadlima to the American government agency. Consequently, Organon will supply Hadlima to hospitals under the Ministry of Veterans Affairs for the next five years.
The Veterans Affairs
The VA is a government agency for veterans in the United States. It provides benefits in various fields, such as medical care and finance, and is building a general hospital-level hospital network and medical infrastructure throughout the United States.
"America's veterans deserve access to quality medicines at a lower cost. We are proud to support the more than nine million people enrolled in the VA healthcare system through this collaboration, which is a great example of industry and public sector working together," Kevin Ali, Organon CEO, said in a press release. "We applaud the VA for its leadership in championing biosimilars and including all three of Organon's biosimilars available in the US on its formulary."
Photo by: Organon Media
